Accelr8 Shares up 60 Percent on MRSA Dx Patent Allowance | GenomeWeb
NEW YORK (GenomeWeb News) — Shares in Accelr8 were up more than 60 percent this afternoon after the company said the US Patent and Trademark Office gave it a notice of allowance on the first patent related to its diagnostic platform.
 
Shares in the company were up 1.36 at $3.82 in late-afternoon trading today.
 
The company said the methods covered by the patent will enable its BACcel system to "quickly identify major multiple-drug-resistant bacteria and their resistance mechanisms."
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.